The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Janux Therapeutics Inc shares valued at $5,180,839 were sold by Avalon Ventures XI, L.P. on Sep 26 ’24. At $47.23 per share, Avalon Ventures XI, L.P. sold 109,700 shares. The insider’s holdings dropped to 555,727 shares worth approximately $24.55 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Avalon Ventures XI, L.P. sold 90,300 shares, netting a total of over 4,264,629 in proceeds. Following the sale of shares at $47.23 each, the insider now holds 2,868,875 shares.
Before that, Avalon Ventures XI, L.P. had sold 57,590 shares from its account. In a trade valued at $2,675,750, the 10% Owner traded Janux Therapeutics Inc shares for $46.46 each. Upon closing the transaction, the insider’s holdings decreased to 57,590 shares, worth approximately $24.14 million.
As published in their initiating research note from Stifel on September 06, 2024, Janux Therapeutics Inc [JANX] has been a Buy and the price target has been revised to $70. Analysts at Scotiabank started covering the stock with ‘”a Sector perform”‘ outlook in a report released in late May. As of March 21, 2024, BTIG Research has initiated its “Buy” rating for JANX. Earlier on March 20, 2024, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for JANX stock.
Analyzing JANX Stock Performance
During the last five days, there has been a drop of approximately -5.26%. Over the course of the year, Janux Therapeutics Inc shares have jumped approximately 311.65%. Shares of the company reached a 52-week high of $65.60 on 05/03/24 and a 52-week low of $7.79 on 02/05/24. A 50-day SMA is recorded $43.76, while a 200-day SMA reached $36.49. Nevertheless, trading volume fell to 0.63 million shares from 0.59 million shares the previous day.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 43.11, which, if violated, would cause prices to drop to 42.06. In the upper region, resistance lies at 45.11. The next price resistance is at 46.06. RSI (Relative Strength Index) is 44.37 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -3.46, which suggests the price will decrease in the coming days. Percent R is at 83.18%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
